Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers

Serwaa, Dorcas; Osei‐Boakye, Felix; Nkansah, Charles; Ahiatrogah, Selasie; Lamptey, Emmanuel; Abdulai, Ratif; Antwi, Maxwell Hubert; Wirekoh, Eric Yaw; Owusu, Ernest; Buckman, Tonnies Abeku; Danquah, Mark

doi:10.1080/21645515.2021.1963600

Cited by 16 publications

(20 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 25 Compared to Bangladesh, higher vaccine reactogenicity has been reported in studies of HCPs in India (65.9% 26 and 69.7% 27 ), South Korea (99.8%, 28 98.1%, 29 90.9%, 30 and 93% 31 ), Germany, Czech Republic (94.6%), 32 Togo (71.6%), 33 Nepal (85%), 34 Saudi Arabia (96.1%), 35 Ethiopia (68.4%) 36 and Ghana (80.7%). 37 However, lower rates were found among HCPs in two studies from India—40% 38 and 56.9%. 22 These disparities may be due to greater representation of elderly participants (≥65 years), as older adults generally exhibit milder symptoms.…”

Section: Discussionmentioning

confidence: 94%

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

et al. 2022

View full text Add to dashboard Cite

Increased COVID‐19 vaccine hesitancy presents a major hurdle in global efforts to contain the COVID‐19 pandemic. This study was designed to estimate the prevalence of adverse events after the first dose of the Covishield (AstraZeneca) vaccine among physicians in Bangladesh. A cross‐sectional study was conducted using an online questionnaire for physicians ( n = 916) in Bangladesh. Physicians who received at least one dose of the COVID‐19 vaccine were included. The study was carried out from April 12 to May 31, 2021. More than 58% of respondents ( n = 533) reported one or more adverse events. Soreness of the injected arm (71.9%), tiredness (56.1%), fever (54.4%), soreness of muscles (48.4%), headache (41.5%) and sleeping more than usual (26.8%) were the most commonly reported adverse events. Most vaccine‐related reactogenicities were reported by the younger cohorts (<45 years). The majority of respondents reported severity of reactogenicity as “mild,” experienced on the day of vaccination, and lasting for 1–3 days. The most common reactogenicity was pain at the injection site; the second most common was tiredness. Almost half (49.2%) of the physicians took acetaminophen (paracetamol) to minimize the effects of vaccine reactogenicity. Multivariate logistic regression analyses showed that physicians with diabetes and hypertension (OR = 2.729 95% CI: 1.282–5.089) and asthma with other comorbidities (OR = 1.885 95% CI: 1.001–3.551) had a significantly higher risk of vaccine‐related reactogenicities than physicians without comorbidities. Further safety studies with larger cohorts are required to monitor vaccine safety and provide assurance to potential vaccine recipients.

show abstract

Section: Discussionmentioning

confidence: 94%

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Studies elsewhere in Africa, such as Ghana reported higher rates of at least one side effect (81%) among healthcare workers ( 20 ). Nonetheless, the prevalenve of headache and fever among healthcare workers after receiving the Oxford AstraZeneca COVID-19 vaccine in Ethiopia is similar with Ghana.…”

Section: Discussionmentioning

confidence: 99%

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Yesuf

Riad²,

Sofi‐Mahmudi³

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

IntroductionEthiopia is the second most populous country in Africa. Ethiopia received most of its COVID-19 vaccines through donations. The Oxford AstraZeneca vaccine is the first to be donated to Ethiopia by the COVAX facility. Healthcare workers were the priority population that received the Oxford AstraZeneca COVID-19 vaccine. However, there was no nationwide study on the safety of the vaccine in Ethiopia. This study aimed to measure the prevalence and predictors of self-reported side effects of the Oxford AstraZeneca vaccine.Materials and methodsThe study employed a cross-sectional design. A sample of healthcare workers who took Oxford AstraZeneca COVID-19 vaccine was drawn from four regions of Ethiopia; namely, Amhara, Oromia, Somali, and Southwest. Data were collected on sociodemographic characteristics, medical anamnesis, COVID-19 related anamnesis, and COVID-19 vaccine anamnesis via telephone interview. Descriptive and inferential analyses were done. The software, IBM SPSS Statistics v21.0, was used for analyses of data.ResultsOut of 384 people, 346 responded (response rate: 90.1%). Female accounted for 34.1% of the respondents. The mean age of the respondents was 31.0 years (Standard Deviation (SD) = 7.4). Nurses accounted for 43.7% of the respondents. The prevalence of at least one local- and systemic-side effect was 50.6 and 44.5%, respectively. The most frequent local- and systemic- side effect were injection site pain and headache, respectively. Both types of side effects mostly subsided in the first 3 days. A third of healthcare workers with side effects took at least one medication. Paracetamol followed by diclofenac sodium were taken by healthcare workers to overcome side effects. There was no independent predictor of local side effect. After controlling for age and chronic diseases, the odds of healthcare workers with COVID-19 like symptoms to experience systemic side effects was 1.38 (Confidence Interval (CI): 1.04–1.82) times more than that of healthcare workers without COVID-19 like symptoms.ConclusionsThe prevalence of local- and systemic-side effects of the Oxford AstraZeneca COVID-19 vaccine was modest. As the symptoms were mostly common in the first 3 days, it is preferable to monitor healthcare workers at least in the first 3 days following the administration of the vaccine.

show abstract

“…They found that 7% of recipients experienced headache after the first dose of Pfizer while 22% developed headache after the first dose of AstraZeneca. Another study found that the AstraZeneca vaccine caused non-life-threatening side effects [35]. Denis Logonov and colleagues published interim results from a Phase III study of the Sputnik V COVID-19 vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…Some studies reported the side effects of the Pfizer vaccine [26][27][28][29][30][31][32][33], although the findings support no unusual patterns of adverse events following two doses of the COVID-19 vaccine; the majority of these reactions were mild to moderate. Studies describing the side effects of the AstraZeneca vaccine are also limited, with reported symptoms similar in type and severity to those of the Pfizer vaccine [29][30][31]34,35]. Although there are worries regarding the safety of the AstraZeneca vaccine following instances of blood clots, it has been observed that post-vaccination neurological problems are uncommon [30].…”

Section: Introductionmentioning

confidence: 99%

Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study

Zahid

2021

Vaccines

View full text Add to dashboard Cite

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) created a global pandemic (COVID-19) that has resulted in massive health and economic losses. The current unavailability of treatments leaves vaccination as the only way to control this disease. There are four vaccines (Sinopharm, Pfizer—BioNTech, Sputnik, and AstraZeneca) available in Bahrain. This project aimed to study the most common side effects resulting from the first and second doses of these four vaccines. Data were collected through an online questionnaire answered by 311 individuals who received both doses of one of these four vaccines. The results of this study revealed that regardless of the vaccine identity, participants experienced more side effects from the second dose. Among the different side effects, pain at the site of injection was primarily observed after the first dose of the Pfizer vaccine (43%), which was followed by the AstraZeneca vaccine (31%). Moreover, fever was observed in participants after the first dose of the Sputnik vaccine (37%), while headache was mainly observed after the first dose of the Pfizer vaccine (32%). It is important to note that fatigue was observed after the first dose of all four vaccines but was reported by the highest proportion of respondents in the Pfizer group (28%). Interestingly, there are some side effects, such as pain at the site of injection, that are correlated with fever (r = 0.909). Similarly, headache is correlated with fever (r = 0.801) and pain at the site of injection (r = 0.868). Overall, it was observed that recipients of the Sinopharm vaccine reported the mildest side effects among all four vaccines. The crucial finding of this study is that the first and second dosage post-vaccination side effects were modest and predictable with no occurrences of hospitalization; this information can assist in lessening vaccine apprehension.

show abstract

Non-life-threatening adverse reactions from COVID-19 vaccine; a cross-sectional study with self-reported symptoms among Ghanaian healthcare workers

Cited by 16 publications

References 18 publications

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians

Self-reported side effects of the Oxford AstraZeneca COVID-19 vaccine among healthcare workers in Ethiopia, Africa: A cross-sectional study

Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study

Contact Info

Product

Resources

About